Zenas Biopharma Inc (ZBIO) saw an uptrend of 23.01% in the recent trading with $19.78 being its most recent. The current price level -55.65% lower than the highest price of $44.60 marked by the stock while trading over the past 52-weeks, whereas it is 239.28% higher than the lowest price of $5.83 the company dropped to over past 52-weeks. The latest news story on ZBIO appeared in (Benzinga) under the title “Benzinga’s ‘Stock Whisper’ Index: 5 Stocks Investors Secretly Monitor But Don’t Talk About Yet”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.25 for the stock.
Zenas Biopharma Inc Earnings – What Happened With ZBIO
Coming around sales and income figures on ZBIO Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
Zenas Biopharma Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 42.21 million. ZBIO does have institutional investors; and they hold 31.11% of the stock.
Key Metrics for ZBIO
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Zenas Biopharma Inc has a debt to equity ratio of 0.00.
